PMID- 31062729
OWN - NLM
STAT- MEDLINE
DCOM- 20190904
LR  - 20190904
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 56
IP  - 2
DP  - 2019 Apr-Jun
TI  - FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma.
PG  - 119-123
LID - 10.4103/ijc.IJC_333_18 [doi]
AB  - AIM: The aim of this study was to validate the role of fluorescence in situ 
      hybridization (FISH) in investigating HER2/neu gene amplification (human 
      epidermal growth factor receptor 2) in patients with HER2/neu equivocal breast 
      cancer diagnosed on immunohistochemistry (IHC). MATERIALS AND METHODS: This was a 
      retrospective study conducted from January 2013 to October 2017. A total of 134 
      patients diagnosed with invasive breast carcinoma and HER2/neu equivocal status 
      on IHC were analyzed. Also, the cases for the years 2016 and 2017 formed a 
      subgroup that was analyzed further to study the impact of pre-analytical factors 
      on IHC and FISH results. RESULTS: A total of 134 women with HER2/neu IHC 
      equivocal breast cancer were included in the study with a median age of 50 years 
      (range 25-81). HER2/neu amplification by FISH was noted in 72 (54%) cases, 
      whereas it was non-amplified in 52 (39%) cases. Ten cases were reported as 
      equivocal even on FISH (ASCO/CAP 2013 guidelines). Polysomy 17 was noted in 55 
      cases (41%), of which 26 patients were</=50 years and 29 patients were >50 years of 
      age. Twenty (36%) of these 55 cases showed HER2/neu amplification, whereas 26 
      (48%) cases were non-amplified and 9 (16%) cases were reported as equivocal on 
      FISH. Also, more than half of the polysomy cases were hormone receptor negative. 
      CONCLUSION: IHC is a good screening tool for negative and positive results. Any 
      patient targeted for trastuzumab therapy should undergo confirmation of HER2/neu 
      equivocal status by FISH analysis. We also suggest that if a non-classical FISH 
      pattern is seen, the test should be repeated with a non-centromeric chromosome 17 
      reference locus probe for better treatment planning.
FAU - Patil Okaly, Geeta Vikram
AU  - Patil Okaly GV
AD  - Department of Pathology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.
FAU - Panwar, Dipti
AU  - Panwar D
AD  - Department of Pathology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.
FAU - Lingappa, Kavitha Bidadli
AU  - Lingappa KB
AD  - Department of Pathology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.
FAU - Kumari, Prasanna
AU  - Kumari P
AD  - Department of Pathology, Cytogenetics Unit, Kidwai Cancer Institute, Bengaluru, 
      Karnataka, India.
FAU - Anand, Abhishek
AU  - Anand A
AD  - Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, 
      India.
FAU - Kumar, Prashantha
AU  - Kumar P
AD  - Department of Pathology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.
FAU - Chikkalingaiah, Manju Hosur
AU  - Chikkalingaiah MH
AD  - Department of Pathology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.
FAU - Kumar, Rekha Vijay
AU  - Kumar RV
AD  - Department of Pathology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*diagnosis/genetics/pathology
MH  - Chromosome Aberrations
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Receptor, ErbB-2/genetics/*isolation & purification
MH  - Retrospective Studies
MH  - Trastuzumab/therapeutic use
OTO - NOTNLM
OT  - Breast carcinoma
OT  - FISH
OT  - HER2/neu
OT  - immunohistochemistry
COIS- None
EDAT- 2019/05/08 06:00
MHDA- 2019/09/05 06:00
CRDT- 2019/05/08 06:00
PHST- 2019/05/08 06:00 [entrez]
PHST- 2019/05/08 06:00 [pubmed]
PHST- 2019/09/05 06:00 [medline]
AID - IndianJournalofCancer_2019_56_2_119_257551 [pii]
AID - 10.4103/ijc.IJC_333_18 [doi]
PST - ppublish
SO  - Indian J Cancer. 2019 Apr-Jun;56(2):119-123. doi: 10.4103/ijc.IJC_333_18.